Organon & Co(OGN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 17.61 | EPS (ttm) | 0.78 | Insider Own | 0.64% | Shs Outstand | 262.6M | Perf Week | -0.07% |
| Market Cap | 3.61B | Forward P/E | 3.79 | EPS next Y | 8.36% | Insider Trans | 0.7% | Shs Float | 260.9M | Perf Month | 0.15% |
| Enterprise Value | 11.03B | PEG | 1.23 | EPS next Q | 0.88 | Inst Own | 83.3% | Short Float | 7.21% | Perf Quarter | 1.55% |
| Income | 0.21B | P/S | 0.59 | EPS this Y | -8.47% | Inst Trans | -0.13% | Short Ratio | 7.29 | Perf Half Y | 3.23% |
| Sales | 6.13B | P/B | 3.59 | EPS next 5Y | 3.09% | ROA | 1.57% | Short Interest | 18.82M | Perf YTD | 91.77% |
| Book/sh | 3.83 | P/C | 3.19 | EPS past 3/5Y | -41.56% -39.04% | ROE | 24.04% | 52W High | -0.58% ($13.83) | Perf Year | 94.76% |
| Cash/sh | 4.31 | P/FCF | 6.37 | Sales past 3/5Y | 0.23% -1% | ROIC | 2.2% | 52W Low | 141.65% ($5.69) | Perf 3Y | -8.09% |
| Dividend Est. | $0.08 (0.58%) | EV/EBITDA | 7.18 | EPS Y/Y TTM | -70.52% | Gross Margin | 53.09% | Volatility(W/M) | 0.19% 0.29% | Perf 5Y | -61.51% |
| Dividend TTM | 0.08 | EV/Sales | 1.8 | Sales Y/Y TTM | -2.45% | Oper. Margin | 19.41% | ATR (14) | 0.04 | Perf 10Y | - |
| Dividend Ex-Date | 2026/8/14 | Quick Ratio | 1.44 | EPS Q/Q | -28.36% | Profit Margin | 3.41% | RSI (14) | 52.76 | Recom | 3 |
| Dividend Gr. 3/5Y | -32.79% - | Current Ratio | 1.95 | Sales Q/Q | -2.26% | SMA20 | 0.01% ($13.75) | Beta | 1.53 | Target Price | $14 |
| Payout | 47.41% | Debt/Eq | 8.5 | Earnings | 2026/08/11 | SMA50 | 0.14% ($13.73) | Rel Volume | 0.72 | Prev Close | $13.74 |
| Employees | 10000 | LT Debt/Eq | 8.43 | EPS/Sales Surpr. | -6.59% - | SMA200 | 20.24% ($11.44) | Avg Volume(3M) | 2.58M | Price | $13.75 |
| IPO | 2021/5/14 | Option/Short | Yes/Yes | Trades | 6414 | Volume | 1,865,174 | Change | 0.07% |
A global pharmaceutical company that sells women's health products, biosimilars, and established medications. It supplies women's health drugs, biosimilars, and a diverse portfolio of established brand-name pharmaceuticals to global markets, and is characterized by strong cash flow and dividends. It is a pharmaceutical company specializing in women's health.
Over the past 1 year, on the higher side
1% below its 1-year high.
Traded less than usual. That is 72% of its average volume.
OGN has weak earnings and a weak balance sheet
After all costs, only $3.41 of every $100 in sales is left.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -8.5% this year.
Tap to view numbers
Within its industry, it looks cheap
Counting its debt, for $100 of yearly operating cash you would pay $718. Peers typically go for $1,470. Compared with its own 5-year average, it is 184% pricier now.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -61.5%. The S&P 500 did +70% over the same period.
Tap to view numbers
The dividend is on the small side
Pays 0.58% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 83.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #15 of 21 in the industry
Based on market cap of $4B.
SNY#13 Sanofi ADR $100B PER 21.6 
BIIB#14 Biogen Inc $37B PER 44.8 OGN#15 Organon & Co $4B PER 17.6 
GRFS#16 Grifols SA ADR $2B PER 10.4 
AMRN#17 Amarin Corp ADR $252M PER - 
FAQ
What kind of company is OGN?
OGN belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.
What is the market cap of OGN?
The market cap of OGN is approximately $3.6B, ranking 1,614 within its sector.
Does OGN pay dividends?
OGN has a dividend yield of approximately 0.58%, with an annual dividend of $0.08.
What is the P/E ratio of OGN?
OGN has a P/E ratio of approximately 17.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for OGN?
OGN has recorded a 52-week high of $13.83 and a low of $5.69.
